A recent study revealed that overexpression of ABC transporters was responsible for acquired resistance to antibody-drug conjugate (ADC) in cancer immunotherapy, and combinational administration of ABC transporter inhibitors increased the response rate of immunotherapy in resistant cancer cells (Chen et al., 2020). This evidence concerns the gene ABCG2 and cancer.